Janssen Presents Initial Results from the Phase 2 RAGNAR Study of Erdafitinib in Patients with Advanced Solid Tumours with FGFR Alterations
- EMEA Innovative Medicine
- Janssen Presents Initial Results from the Phase 2 RAGNAR Study of Erdafitinib in Patients with Advanced Solid Tumours with FGFR Alterations
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of Erdafitinib in Patients with Advanced Solid Tumours with FGFR Alterations
- X (Twitter)
Copy link